Montero Stephanie, Urrunaga-Pastor Diego, Soto-Becerra Percy, Cvetkovic-Vega Aleksandar, Guillermo-Roman Martina, Figueroa-Montes Luis, Sagástegui Arturo A, Alvizuri-Pastor Sergio, Contreras-Macazana Roxana M, Apolaya-Segura Moisés, Díaz-Vélez Cristian, Maguiña Jorge L
Instituto de Evaluación de Tecnologías en Salud e Investigación - IETSI, ESSALUD, Lima, Peru.
Unidad para la Generación y Síntesis de Evidencias en Salud, Universidad San Ignacio de Loyola (USIL), Lima, Peru.
Vaccine X. 2023 May 5;14:100311. doi: 10.1016/j.jvacx.2023.100311. eCollection 2023 Aug.
The inactivated virus vaccine, BBIBP-CorV, was principally distributed across low- and middle-income countries as primary vaccination strategy to prevent poor COVID-19 outcomes. Limited information is available regarding its effect on heterologous boosting. We aim to evaluate the immunogenicity and reactogenicity of a third booster dose of BNT162b2 following a double BBIBP-CorV regime.
We conducted a cross-sectional study among healthcare providers from several healthcare facilities of the Seguro Social de Salud del Perú - ESSALUD. We included participants two-dose BBIBP-CorV vaccinated who presented a three-dose vaccination card at least 21 days passed since the vaccinees received their third dose and were willing to provide written informed consent. Antibodies were determined using LIAISON® SARS-CoV-2 TrimericS IgG (DiaSorin Inc., Stillwater, USA). Factors potentially associated with immunogenicity, and adverse events, were considered. We used a multivariable fractional polynomial modeling approach to estimate the association between anti-SARS-CoV-2 IgG antibodies' geometric mean (GM) ratios and related predictors.
We included 595 subjects receiving a third dose with a median (IQR) age of 46 [37], [54], from which 40% reported previous SARS-CoV-2 infection. The overall geometric mean (IQR) of anti-SARS-CoV-2 IgG antibodies was 8,410 (5,115 - 13,000) BAU/mL. Prior SARS-CoV-2 history and full/part-time in-person working modality were significantly associated with greater GM. Conversely, time from boosting to IgG measure was associated with lower GM levels. We found 81% of reactogenicity in the study population; younger age and being a nurse were associated with a lower incidence of adverse events.
Among healthcare providers, a booster dose of BNT162b2 following a full BBIBP-CorV regime provided high humoral immune protection. Thus, SARS-CoV-2 previous exposure and working in person displayed as determinants that increase anti-SARS-CoV-2 IgG antibodies.
灭活病毒疫苗BBIBP-CorV主要在低收入和中等收入国家作为预防严重COVID-19结局的主要疫苗接种策略进行分发。关于其对异源加强免疫的影响，目前可用信息有限。我们旨在评估在两剂BBIBP-CorV接种方案后，第三剂BNT162b2加强针的免疫原性和反应原性。
我们对来自秘鲁社会保障健康保险（ESSALUD）多个医疗机构的医护人员进行了一项横断面研究。我们纳入了接种过两剂BBIBP-CorV且在接种第三剂疫苗至少21天后出示了三剂疫苗接种卡并愿意提供书面知情同意书的参与者。使用LIAISON® SARS-CoV-2三聚体IgG（美国斯蒂尔沃特的DiaSorin公司）测定抗体。考虑了可能与免疫原性和不良事件相关的因素。我们使用多变量分数多项式建模方法来估计抗SARS-CoV-2 IgG抗体几何平均（GM）比值与相关预测因素之间的关联。
我们纳入了595名接受第三剂疫苗的受试者，年龄中位数（四分位间距）为46岁[37, 54]，其中40%报告曾感染过SARS-CoV-2。抗SARS-CoV-2 IgG抗体的总体几何平均（四分位间距）为8410（5115 - 13000）BAU/mL。既往SARS-CoV-2感染史以及全职/兼职现场工作模式与更高的GM显著相关。相反，从加强免疫到IgG检测的时间与较低的GM水平相关。我们在研究人群中发现81%有反应原性；年龄较小和为护士与不良事件发生率较低相关。
在医护人员中，完整的BBIBP-CorV接种方案后接种一剂BNT162b2加强针可提供高度的体液免疫保护。因此，既往SARS-CoV-2暴露和现场工作表现为增加抗SARS-CoV-2 IgG抗体的决定因素。
